Bart Scott, MD, Professor, Transplantation Program, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about the Highlights of ASH 2022 – Hematopoietic Stem Cell Transplantation.
Hematopoietic stem cell transplantation (HSCT) is an intravenous infusion of hematopoietic stem cells used to restore blood cell production in individuals with damaged or dysfunctional bone marrow or immune systems. This approach has been utilized to treat a variety of malignant and nonmalignant disorders with increasing frequency during the last half-century.
Cells for HSCT can be taken from the patient (autologous transplant), a sibling or unrelated donor (allogeneic transplant), or an identical twin (allogeneic transplant) (syngeneic transplant). Bone marrow, peripheral blood, umbilical cord blood, and, in rare cases, fetal liver are all possible cell sources.